A Phase II Clinical Trial of Artificial Intelligence-assisted One-stop Radiotherapy for Breast Cancer After Breast-conserving Surgery

NCT06686459 · tracked via the Priya Life Science China tracker

Sponsor

Sun Yat-sen University

Phase

Not applicable

Started

2025-04-06

Last updated

2025-07-01

Condition(s) studied

Breast Cancer Invasive

Investigational drug(s) / intervention(s)

ALL-in-one radiotherapyIMRT

ALL-in-one radiotherapy: ALL-in-one radiotherapy (breast + supraclavicular + internal mammary lymph node drainage area)

IMRT: IMRT (breast + supraclavicular + internal mammary lymph node drainage area)

Study summary

Background: Breast cancer became the most prevalent cancer globally in 2020, and post-surgery radiotherapy is crucial for most patients. Traditional radiotherapy is complex and time-consuming, affecting patient experience. To streamline this, an AI-assisted All-in-one (AIO) radiotherapy approach has been developed, integrating steps like target delineation and planning to reduce wait times and enhance accuracy. Preliminary results are promising, with significant time savings and high pass rates in initial assessments. Further exploration is needed to confirm the accuracy, effectiveness, and safety of AIO radiotherapy.

Primary objective: To conduct a prospective phase II clinical trial to determine the feasibility (including efficacy and safety) of AIO radiotherapy, and to provide a basis for establishing standard operating procedures.

Secondary objectives: To assess the impact of AIO radiotherapy on overall survival, local regional recurrence, and distant metastasis rates. To investigate the incidence and contributing factors of cardiac damage after AIO radiotherapy.

Eligibility

Sex

FEMALE

Min age

18 Years

Max age

70 Years

Healthy volunteers

Inclusion Criteria: * 1\. Female patients aged 18-70 years. 2. ECOG performance status of 0-2. 3. Newly diagnosed invasive breast cancer, underwent breast-conserving surgery plus axillary lymph node dissection, with positive axillary lymph nodes (ypN+) and negative surgical margins. 4\. No distant metastasis. 5. Capable of tolerating radiotherapy. 6. For ER/PR-positive patients, willing to receive anticipated 5 years of endocrine therapy. 7\. For HER2-positive patients, willing to receive anticipated 1 year of anti-HER2 targeted therapy. 8\. For patients requiring neoadjuvant/adjuvant chemotherapy, must have completed chemotherapy. 9\. Left ventricular ejection fraction (LVEF) measured by echocardiography is 50%. 10\. Must undergo adjuvant IMRT (Intensity-Modulated Radiation Therapy). 11. Capable of tolerating lying still on the treatment accelerator bed for 30 minutes to complete All-In-One radiotherapy. 12\. Have follow-up conditions and are willing to adhere to follow-up. 13. Signed an informed consent form. Exclusion Criteria: * 1\. Synchronous bilateral breast cancer; sentinel lymph node biopsy of the axilla was performed without axillary lymph node dissection. 2\. Stage I breast reconstruction surgery or expander implantation surgery on the affected side chest wall. 3\. The purpose of radiotherapy is palliative. 4. Myocardial infarction within the last 3 months or uncorrected unstable arrhythmia or uncorrected unstable angina. 5\. History of chest wall or supraclavicular radiotherapy in the past; past or concurrent second primary malignant tumors (except for non-melanoma skin cancer, papillary/follicular thyroid carcinoma, and carcinoma in situ of the cervix). 6\. All-in-one one-stop radiotherapy has not been completed.

Primary outcome measure(s)

incidence rate of adverse effects — 12 months after the end of radiotherapy

Trial sites (1)

Facility	City	Region	Status
Sun Yat-sen University Cancer Center	Guangzhou	China	Recruiting

More Sun Yat-sen University trials in China

Sodium Bicarbonate for Reducing Radiation-Induced Oral Mucositis in Nasopharyngeal Carcinoma. Active, not recruiting

A Phase I/II Study of Golidocitinib Combined with Pomalidomide in R/R PTCL Recruiting

Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLC Starting soon

BRIDGE Study: Neoadjuvant Finotonlimab, Cetuximab, and Docetaxel in Resectable Recurrent HNSCC After Immunotherapy Progression Enrolling by invitation

Maintenance Immunotherapy With Deferred Salvage Radiotherapy After Response to Chemoimmunotherapy in Recurrent Nasopharyngeal Carcinoma Recruiting

Other trials for the same condition

The Association Between Axillary Lymph Node Metastasis Patterns and Breast Cancer Prognosis Active, not recruiting

Long-Term Outcomes of Endoscopic-assisted vs Conventional Breast-conserving Surgery in Breast Cancer Patients After Neoadjuvant Therapy: a Randomized, Multicenter, Open Label, Non-inferiority Trial Recruiting

Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer Active, not recruiting

GzmB-PET/CT to Evaluate Neoadjuvant Therapy Efficacy in Breast Cancer Recruiting

The Association Between Blood Routine Parameters and Breast Cancer Prognosis Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06686459 on ClinicalTrials.gov ↗ ← All trials in China